A Phase 2 interventional study of Mesenchymal stem cells and Placebo in COVID-19, sponsored by Dr. Zaineb Akram. Status unknown at 1 site in Pakistan. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2020-06-30.
Sponsored by Dr. Zaineb Akram · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in COVID-19 with a site in Pakistan — 3 open to participants now, 4 under way, 2 of them phase 3. COVID-19 · Pakistan.
Among the 98 studies in COVID-19 with a site in Pakistan, this one is the 67th largest by planned enrollment of the 71 interventional ones that give a count, is one of 62 that started in 2020, is one of 7 in phase 2, and was the 15th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 98 studies in COVID-19 with a site in Pakistan are open now. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 18–25 · Healthy volunteers
University of Oxford · Sites in Pakistan, Brazil, Laos and 2 more countries
Ages 18–60
UMC Utrecht · Sites in Pakistan, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 62 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 125 across the 71 interventional studies, 373 across the 27 observational. Of the 68 that completed or were terminated, 5 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 98 have an industry lead sponsor. The 10 most frequent:
Dr. Zaineb Akram is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Dr. Zaineb Akram has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies in COVID-19 with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have carried out/published clinical trials on treatment based on Western medicine, traditional Chinese medicine or a combination of the two. Trials on treatment modalities have mainly used antivirals, interferon, glucocorticoids in addition to traditional Chinese medicine. There are also clinical trials exploring hydroxyquinoline/chloroquine sulphate, immunoglobulins, Vitamin-C, washed microbiota, nebulized interferon, teicoplanin as well as Mesenchymal stem cells. However, most of these trials were small (median sample size 100) and the bulk of potential therapeutic strategies remain in the experimental phase and currently there is no effective specific antiviral with high-level evidence.The aim of this study is assess the efficacy of MSCs as an add-on therapy to standard supportive treatment for patients with moderate/severe COVID-19.
All patients will receive 2x10\^6 cells/kg on days 1 and day 7 (if needed). The study will be divided in 2 phases. In the first phase, 10 patients will be included and randomized to 2 groups (5 Treatment arm; 5 Control Arm) and receive 2 x10\^6 cells/kg MSCs on days 1 and 7 in addition to standard care. Thereafter, the trial committee will meet and evaluate all collected safety and efficacy information to decide about crossover of Control arm to treatment arm if patient deteriorates clinically while in Control arm. Then, 10 new subjects will be included in the study and treated according to protocol.
Preparation of MSCs doses MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37oC in 5% carbondioxide (CO2). Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- Ethylenediaminetetraacetic acid ( EDTA ) solution. The prepared cells can either be stored in 50ml cryogenic vials for future use or infused immediately.
Patient Selection and MSCs demand Patient for MSCs and Control arm will be selected by multidisciplinary team (MDT) comprising Critical Care Specialist, Pulmonologist, Infectious Disease Specialist, Clinical Hematologist.
Proposed usage:
Because of the very limited availability of MSCs, their usage has to be rationalized by MDT comprising of pulmonologist, critical care specialist and clinical haematologist and Infectious disease specialist.There is not enough evidence to put forth therapeutic recommendations however, treatment decisions can be made on case to case basis after MDT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 patients will be given mesenchymal stem cells at dose 2x10\^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
Drug: Mesenchymal stem cells
Only supportive care will be given to 10 patients
Other: Placebo
1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
Also known as: MSCs
100 ml of normal saline will be given intravenously to control arm
Overall survival
Assessment of Overall survival at 30 days post intervention
Time frame: 30 days post intervention
Clinical improvement
days required for oxygen support independence after intervention
Time frame: 30 days
Time of COVID19 PCR negativity
PCR testing to check PCR negativity
Time frame: day 1,3,7,10, 14
Radiological improvement (day 15 and day 30 assessment)
Computed tomography Chest assesment will be done to assess improvment in radiological findings of COVID-19
Time frame: day 15 and day30
days required to discharge from hospital
number of days required for discharge from hospital
Time frame: 30 days post admission
Plan to share: No
No publications or documents are linked to this record.
Started May 2020 (actual). Primary completion is estimated for Aug 2020, 3 months after the start.
Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Zaineb Akram